A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy
Objective
Primary Objective: To compare the effect of SG relative to the TPC on PFS.
Key Secondary Objective: To compare the effect of SG relative to TPC on the following: OS, ORR, Change from baseline in physical functioning domain and time to deterioration (TTD) in Global Health Status/quality of life (QoL) as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQC30).
